Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. 1998

D W Thomas, and R B Mannon, and P J Mannon, and A Latour, and J A Oliver, and M Hoffman, and O Smithies, and B H Koller, and T M Coffman
Department of Medicine, Duke University and Durham Veterans Affairs Medical Centers, Durham, North Carolina 27705, USA.

Thromboxane A2 (TXA2) is a labile metabolite of arachidonic acid that has potent biological effects. Its actions are mediated by G protein-coupled thromboxane-prostanoid (TP) receptors. TP receptors have been implicated in the pathogenesis of cardiovascular diseases. To investigate the physiological functions of TP receptors, we generated TP receptor-deficient mice by gene targeting. Tp-/- animals reproduce and survive in expected numbers, and their major organ systems are normal. Thromboxane agonist binding cannot be detected in tissues from Tp-/- mice. Bleeding times are prolonged in Tp-/- mice and their platelets do not aggregate after exposure to TXA2 agonists. Aggregation responses after collagen stimulation are also delayed, although ADP-stimulated aggregation is normal. Infusion of the TP receptor agonist U-46619 causes transient increases in blood pressure followed by cardiovascular collapse in wild-type mice, but U-46619 caused no hemodynamic effect in Tp-/- mice. Tp-/- mice are also resistant to arachidonic acid-induced shock, although arachidonic acid signifi-cantly reduced blood pressure in Tp-/- mice. In summary, Tp-/- mice have a mild bleeding disorder and altered vascular responses to TXA2 and arachidonic acid. Our studies suggest that most of the recognized functions of TXA2 are mediated by the single known Tp gene locus.

UI MeSH Term Description Entries
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008811 Mice, Inbred DBA An inbred strain of mouse. Specific substrains are used in a variety of areas of BIOMEDICAL RESEARCH such as DBA/1J, which is used as a model for RHEUMATOID ARTHRITIS. Mice, DBA,Mouse, DBA,Mouse, Inbred DBA,DBA Mice,DBA Mice, Inbred,DBA Mouse,DBA Mouse, Inbred,Inbred DBA Mice,Inbred DBA Mouse
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D001760 Bleeding Time Duration of blood flow after skin puncture. This test is used as a measure of capillary and platelet function. Aspirin Tolerance Test,Bleeding Time, Template,Duke Method,Ivy Method,Template Bleeding Time,Aspirin Tolerance Tests,Bleeding Times,Bleeding Times, Template,Method, Duke,Method, Ivy,Template Bleeding Times,Test, Aspirin Tolerance,Tests, Aspirin Tolerance,Time, Bleeding,Time, Template Bleeding,Times, Bleeding,Times, Template Bleeding,Tolerance Test, Aspirin,Tolerance Tests, Aspirin
D001778 Blood Coagulation Disorders Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions. Coagulation Disorders, Blood,Disorders, Blood Coagulation,Blood Coagulation Disorder,Coagulation Disorder, Blood,Disorder, Blood Coagulation
D003094 Collagen A polypeptide substance comprising about one third of the total protein in mammalian organisms. It is the main constituent of SKIN; CONNECTIVE TISSUE; and the organic substance of bones (BONE AND BONES) and teeth (TOOTH). Avicon,Avitene,Collagen Felt,Collagen Fleece,Collagenfleece,Collastat,Dermodress,Microfibril Collagen Hemostat,Pangen,Zyderm,alpha-Collagen,Collagen Hemostat, Microfibril,alpha Collagen
D005260 Female Females
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic

Related Publications

D W Thomas, and R B Mannon, and P J Mannon, and A Latour, and J A Oliver, and M Hoffman, and O Smithies, and B H Koller, and T M Coffman
July 2000, Proceedings of the National Academy of Sciences of the United States of America,
D W Thomas, and R B Mannon, and P J Mannon, and A Latour, and J A Oliver, and M Hoffman, and O Smithies, and B H Koller, and T M Coffman
October 1995, Journal of lipid mediators and cell signalling,
D W Thomas, and R B Mannon, and P J Mannon, and A Latour, and J A Oliver, and M Hoffman, and O Smithies, and B H Koller, and T M Coffman
August 2007, The Journal of investigative dermatology,
D W Thomas, and R B Mannon, and P J Mannon, and A Latour, and J A Oliver, and M Hoffman, and O Smithies, and B H Koller, and T M Coffman
March 2008, Molecular and cellular neurosciences,
D W Thomas, and R B Mannon, and P J Mannon, and A Latour, and J A Oliver, and M Hoffman, and O Smithies, and B H Koller, and T M Coffman
January 2001, The Journal of biological chemistry,
D W Thomas, and R B Mannon, and P J Mannon, and A Latour, and J A Oliver, and M Hoffman, and O Smithies, and B H Koller, and T M Coffman
April 2004, Molecular and cellular neurosciences,
D W Thomas, and R B Mannon, and P J Mannon, and A Latour, and J A Oliver, and M Hoffman, and O Smithies, and B H Koller, and T M Coffman
July 1996, Nature medicine,
D W Thomas, and R B Mannon, and P J Mannon, and A Latour, and J A Oliver, and M Hoffman, and O Smithies, and B H Koller, and T M Coffman
January 1991, Journal of cardiovascular pharmacology,
D W Thomas, and R B Mannon, and P J Mannon, and A Latour, and J A Oliver, and M Hoffman, and O Smithies, and B H Koller, and T M Coffman
May 1998, The American journal of physiology,
D W Thomas, and R B Mannon, and P J Mannon, and A Latour, and J A Oliver, and M Hoffman, and O Smithies, and B H Koller, and T M Coffman
January 1998, Nature,
Copied contents to your clipboard!